Literature DB >> 10772024

Chelating agents for uranium(VI): 2. Efficacy and toxicity of tetradentate catecholate and hydroxypyridinonate ligands in mice.

P W Durbin1, B Kullgren, S N Ebbe, J Xu, K N Raymond.   

Abstract

Uranium(VI) (UO2(2+), uranyl) is nephrotoxic. Depending on isotopic composition and dosage, U(VI) is also chemically toxic and carcinogenic in bone. Several ligands containing two, three, or four bidentate catecholate or hydroxypyridinonate metal binding groups, developed for in vivo chelation of other actinides, were found, on evaluation in mice, to be effective for in vivo chelation of U(VI). The most promising ligands contained two bidentate groups per chelator molecule (tetradentate) attached to linear 4- or 5-carbon backbones (4-LI, butylene; 5-LI, pentylene; 5-LIO, diethyl ether). New ligands were then prepared to optimize ligand affinity for U(VI) in vivo and low acute toxicity. Five bidentate binding groups--sulfocatechol [CAM(S)], carboxycatechol [CAM(C)], methylterephthalamide (MeTAM), 1,2-hydroxypyridinone (1,2-HOPO), or 3,2-hydroxypyridinone (Me-3,2-HOPO)--were each attached to two linear backbones (4-LI and 5-LI or 5-LIO). Those ten tetradentate ligands and octadentate 3,4,3-LI(1,2-HOPO), an effective actinide chelator, were evaluated in mice for in vivo chelation of 233U(VI) (injection at 3 min, 1 h, or 24 h or oral administration at 3 min after intravenous injection of 233UO2Cl2) and for acute toxicity (100 micromol kg(-1) injected daily for 10 d). The combined efficacy and toxicity screening identified 5-LIO(Me-3,2-HOPO) and 5-LICAM(S) as the most effective low-toxicity agents. They chelate circulating U(VI) efficiently at ligand:uranium molar ratios > or = 20, remove useful amounts of newly deposited U(VI) from kidney and bone at molar ratios > or = 100, and reduce kidney U(VI) levels significantly when given orally at molar ratios > or = 100. 5-LIO(Me-3,2-HOPO) has greater affinity for kidney U(VI) while 5-LICAM(S) has greater affinity for bone U(VI), and a 1:1 mixture (total molar ratio = 91) reduced kidney and bone U(VI) to 15 and 58% of control, respectively--more than an equimolar amount of either ligand alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772024     DOI: 10.1097/00004032-200005000-00008

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  5 in total

1.  Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO).

Authors:  Rebecca J Abergel; Patricia W Durbin; Birgitta Kullgren; Shirley N Ebbe; Jide Xu; Polly Y Chang; Deborah I Bunin; Eleanor A Blakely; Kathleen A Bjornstad; Chris J Rosen; David K Shuh; Kenneth N Raymond
Journal:  Health Phys       Date:  2010-09       Impact factor: 1.316

2.  Stable Chelation of the Uranyl Ion by Acyclic Hexadentate Ligands: Potential Applications for 230U Targeted α-Therapy.

Authors:  Joshua J Woods; Ryan Unnerstall; Abbie Hasson; Diane S Abou; Valery Radchenko; Daniel L J Thorek; Justin J Wilson
Journal:  Inorg Chem       Date:  2022-02-09       Impact factor: 5.436

3.  Desferrithiocin analogue uranium decorporation agents.

Authors:  Raymond J Bergeron; Jan Wiegand; Shailendra Singh
Journal:  Int J Radiat Biol       Date:  2009-04       Impact factor: 2.694

4.  New methodology for the preparation of 3-hydroxy-2-pyridinone (3,2-HOPO) chelators - Reaction of amines with a novel electrophilic 3,2-HOPO precursor.

Authors:  Timothy N Lambert; Sumathi Chittamuru; Hollie K Jacobs; Aravamudan S Gopalan
Journal:  Tetrahedron Lett       Date:  2002-10-07       Impact factor: 2.415

5.  A 3,2-Hydroxypyridinone-based Decorporation Agent that Removes Uranium from Bones In Vivo.

Authors:  Xiaomei Wang; Xing Dai; Cen Shi; Jianmei Wan; Mark A Silver; Linjuan Zhang; Lanhua Chen; Xuan Yi; Bizheng Chen; Duo Zhang; Kai Yang; Juan Diwu; Jianqiang Wang; Yujie Xu; Ruhong Zhou; Zhifang Chai; Shuao Wang
Journal:  Nat Commun       Date:  2019-06-25       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.